Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions

BACKGROUND Human papillomavirus types 16 (HPV-16) and 18 (HPV-18) cause approximately 70% of cervical cancers worldwide. A phase 3 trial was conducted to evaluate a quadrivalent vaccine against HPV types 6, 11, 16, and 18 (HPV-6/11/16/18) for the prevention of high-grade cervical lesions associated...

Descripción completa

Detalles Bibliográficos
Autor Principal: Ruiz Sternberg, Angela Maria
Formato: Artículo (Article)
Lenguaje:Inglés (English)
Publicado: Massachusetts Medical Society 2007
Materias:
Acceso en línea:https://repository.urosario.edu.co/handle/10336/26826
https://doi.org/10.1056/NEJMoa061741

Ejemplares similares